Characterization of rat NCA/CD9 cell surface antigen and its expression by normal and malignant neural cells

Deissler, Helmut; Blass-Kampmann, Sabine; Kindler‐Röhrborn, Andrea; Meyer, Helmut E.; Rajewsky, Manfred F.

doi:10.1002/(sici)1097-4547(19960315)43:6<664::aid-jnr3>3.0.co;2-c

Cited by 13 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many cell surface receptors are involved in the cell adhesion, migration, and invasion of the glioma cells. Among them, the major role is played by integrins or the hyaluronate receptor CD44 in glioma cell-matrix adhesion (Merzak et al 1994; Friedlander et al 1996), and the CD9 molecule is reported to be strongly associated with the integrins (Boucheix et al 1991; Deissler et al 1996; Schmidt et al 1996; Banerjee et al 1997; Kagawa et al 1997).…”

Section: Discussionmentioning

confidence: 99%

“…CD9 was originally characterized as a cell surface antigen on lymphohemopoietic cells (Boucheix and Benoit 1988). Platelets, pre-B-cells, mature oligo-dendrocytes, and Schwann cells are abundant in CD9 (Kersey et al 1981; Jennings et al 1990; Boucheix et al 1991; Griffith et al 1991; Tole and Patterson 1993; Kaprielian et al 1995; Nakamura et al 1996; Banerjee et al 1997; Kagawa et al 1997), and its expression is also detected in astrocytes and microglia in vitro (Deissler et al 1996; Schmidt et al 1996; Dohura et al 2000), as well as in sympathetic neurons, dorsal root ganglion cells, and adrenal chromaffin cells in the early embryonic peripheral nervous system (Griffith et al 1991; Tole and Patterson 1993). CD9 and other tetraspanins have been reported to participate in the activation, adhesion, and motility of cells and in normal and tumor cell growth (Maecker et al 1997).…”

mentioning

confidence: 99%

See 1 more Smart Citation

CD9 Expression in Solid Non-neuroepithelial Tumors and Infiltrative Astrocytic Tumors

Kawashima

Doh‐ura

Mekada

et al. 2002

J Histochem Cytochem.

View full text Add to dashboard Cite

The tetraspan membrane protein CD9 is normally expressed in the mature myelin sheath and is believed to suppress the metastatic potential of certain human tumors. In this study we identified CD9 in a variety of brain tumors by immunohistochemical (IHC) and immunoblotting analyses. We examined 96 tumor samples and three glioma cell lines in addition to a murine brain tumor model of transplanted glioma cells in CD9-deficient mice and control mice. CD9 was expressed not only in solid non-neuroepithelial tumors but also in infiltrative malignant neuroepithelial tumors. Among the neuroepithelial tumors, high-grade astrocytic tumors, including glioblastomas and anaplastic astrocytomas, showed higher immunoreactivity than low-grade cerebral astrocytomas. Thus, CD9 expression in astrocytic tumors correlated with their malignancy. In the murine brain tumor model, transplanted glioma cells were shown to grow and spread through myelinated areas irrespective of the presence or absence of CD9 expression in the recipient's brain. These results indicate that the CD9 expression of astrocytic tumors plays a significant role in the malignancy independent of CD9 expression in the surrounding tissue. This might be explained by the observation that the CD9 molecule is associated with a mitogenic factor, membrane-anchored heparin-binding epidermal growth factor, which is known to be upregulated in malignant gliomas.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

CD9 Expression in Solid Non-neuroepithelial Tumors and Infiltrative Astrocytic Tumors

Kawashima

Doh‐ura

Mekada

et al. 2002

J Histochem Cytochem.

View full text Add to dashboard Cite

show abstract

“…Antibodies and reagents. We used commercially available monoclonal antibodies (mAbs) directed against HSPG (unlabeled and FITC-conjugated; Seikagaku, Tokyo, Japan); CD9 (unlabeled 72F6 from Novocastra, Newcastle, UK and PE-labeled M-L13 from BD Pharmingen, Heidelberg, Germany) and integrin • V ß 5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and the previously described mAbs NCA-1 and NCA-4 (19) recognizing both rat and human CD9. In all experiments, the specificity of these antibodies was confirmed by parallel processing with murine isotypematched control antibodies: IgG 1 and IgG 2a from Southern Biotechnology, Birmingham, AL, USA; IgM, FITC-labeled IgM, and PE-labeled IgG from BD-Pharmingen.…”

Section: Methodsmentioning

confidence: 99%

CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans

Kurzeder

Koppold²,

Sauer³

et al. 2007

Int J Mol Med

View full text Add to dashboard Cite

Recombinant adeno-associated virus (AAV) is a promising non-pathogenic vector in the emerging field of gene therapy. For AAV serotype 2 (AAV-2) infection, experimental evidence points to an involvement of heparan sulphate proteoglycans (HSPG), but also to the existence of additional receptors. We investigated a potential role of the tetraspanin CD9 in AAV-2 infection of breast cancer cells mainly because it binds to the heparin-binding EGF-like growth factor, suggesting that it may also interact with a heparin-binding virus. Among breast cancer cell lines, expression of HSPG or potential AAV-2 (co)-receptors was not found to correlate with transduction efficiency. In complete accordance with the role of CD9, blocking with anti-CD9 antibodies resulted in drastically decreased AAV-2 transduction efficiencies in cell lines with low expression of HSPG. Furthermore, specific inhibition of CD9 expression with siRNA resulted in fewer transgene-positive cells, whereas overexpression of CD9 in the breast cancer cell line T47D as well as in BT8Ca and BT12Ca rat glioma cells (with low background expression of HSPG and CD9) increased the number of AAV-transduced cells. The minimal epitope recognized by antibody 72F6, which most efficiently blocked AAV-mediated transgene expression, was deduced from the specific binding to peptides immobilized on colour-encoded microspheres consisting of the amino acid sequence PKKDV located in the large extracellular loop of CD9. Our results clearly point to an involvement of CD9 in the attachment, uptake or processing of AAV-2 by target cells expressing low amounts of HSPG, which may help to define cell populations accessible in AAVbased therapeutic applications.

show abstract

“…During development CD9 (TSPAN29) is expressed in motorneurons (Tole & Patterson, 1993) and glia precursor cells (Deissler et al, 1996), but in the adult its expression is mainly in CNS and PNS glia (Tole & Patterson, 1993), and it seems that it is more abundant in the PNS than in the CNS (Ishibashi et al, 2004). CD9 is present in human CNS and PNS myelin (Nakamura et al, 1996) and in premyelinating OLs and mature myelinating OLs (Terada et al, 2002).…”

Section: Tetraspanins In Myelinmentioning

confidence: 99%

Characterization of the neuronal proteolipids M6A and M6B and the oligodendroglial tetraspans PLP and TSPAN2 in neural cell process formation

Schrader¹,

de²

View full text Add to dashboard Cite

Characterization of rat NCA/CD9 cell surface antigen and its expression by normal and malignant neural cells

Cited by 13 publications

References 37 publications

CD9 Expression in Solid Non-neuroepithelial Tumors and Infiltrative Astrocytic Tumors

CD9 Expression in Solid Non-neuroepithelial Tumors and Infiltrative Astrocytic Tumors

CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans

Characterization of the neuronal proteolipids M6A and M6B and the oligodendroglial tetraspans PLP and TSPAN2 in neural cell process formation

Contact Info

Product

Resources

About